On October 11, 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, reported that clinical data on the Company’s lead product candidate eftilagimod alpha ("efti" or "IMP321"), a soluble LAG-3Ig fusion protein based on the LAG-3 immune control mechanism, will be presented at two industry conferences in October and November 2019 (Press release, Immutep, OCT 11, 2019, View Source [SID1234540969]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference:

World Immunotherapy Congress as part of Festival of Biologics 2019

Dates:

October 15-17, 2019 (Tuesday, 15th October/ 2.50 p.m. CET)

Venue:

Basel Congress Centre, Basel, Switzerland

Presentation Title:

A soluble LAG-3 protein (eftilagimod alpha) with an anti-PD-1 antibody (pembrolizumab): a new combination in immuno-oncology – mature results of TACTI-mel

Presenter:

Frédéric Triebel, CSO & CMO of Immutep

Conference:

34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)

Dates:

November 6-10, 2019 (Friday, November 8th, 7.00am – 8.00pm EST)

Venue:

Gaylord National Hotel & Convention Center in National Harbor, 201 Waterfront St, Forest Heights, MD 20745, USA

Title:

Initial results from a Phase II study (TACTI-002) in non-small cell lung cancer, or head and neck cancer patients receiving eftilagimod alpha (LAG-3 fusion protein) and pembrolizumab

Poster Number:

343

Authors:

J. Peguero, E. Felip, B. Doger, M. Marjem, E. Carcereny, T. Clay, P. Bajaj, M. Krebs, F. Triebel
All presentations will be made available on the Company’s website at View Source